VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended March 31, 2026, as well as key corporate developments for Multikine.

CEL-SCI Announces Closing of Public Offering

03:00pm, Wednesday, 13'th May 2026
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of public offering.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Announces Pricing of Public Offering.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia.
SÃO PAULO, April 30, 2026 /PRNewswire/ -- Itaú Unibanco Holding S.A. (the "Company") announces to the market that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2
Cel-Sci Corporation (NYSEAMERICAN:CVM - Get Free Report) was down 0.9% on Thursday. The stock traded as low as $3.27 and last traded at $3.31. Approximately 30,767 shares changed hands during mid-day
Cel-Sci Corporation (NYSEAMERICAN:CVM - Get Free Report)'s stock price shot up 6.9% on Wednesday. The company traded as high as $3.60 and last traded at $3.43. 52,583 shares traded hands during tradin

CEL-SCI Reports Fiscal First Quarter 2026 Results

09:00am, Wednesday, 18'th Feb 2026
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.
Cel-Sci Corporation (NYSEAMERICAN:CVM - Get Free Report)'s stock price was down 6.5% during trading on Friday. The stock traded as low as $5.44 and last traded at $5.48. Approximately 58,410 shares tr

CEL-SCI Reports Fiscal 2025 Results

09:00am, Monday, 29'th Dec 2025
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.
Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executiv
Vienna, Virginia--(Newsfile Corp. - October 10, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Off
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of $10 million public offering.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI announces pricing of $10 million public offering.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE